Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2962712 | 0.88 | FUCA1 (0.58) | S1PR5S1PR1FUCA1TSHRHPGD | |
| SCHEMBL4692050 | 0.83 | GRIN2B (0.58) | S1PR5S1PR1FUCA1KMT2AMEN1 | |
| SCHEMBL7685605 | 0.83 | GRIN2B (0.58) | S1PR5S1PR1FUCA1KMT2AMEN1 | |
| SCHEMBL10410773 | 0.82 | KDM4E (0.50) | ALDH1A1KDM4E | |
| SCHEMBL2852290 | 0.81 | FUCA1 (0.51) | S1PR5S1PR1FUCA1KMT2AMEN1 | |
| SCHEMBL21220647 | 0.81 | FUCA1 (0.51) | S1PR5S1PR1FUCA1KMT2AMEN1 | |
| SCHEMBL21238086 | 0.81 | FUCA1 (0.51) | S1PR5S1PR1FUCA1KMT2AMEN1 | |
| SCHEMBL14529645 | 0.81 | ALDH1A1 (0.53) | S1PR5S1PR1FUCA1ALDH1A1 | |
| SCHEMBL20417932 | 0.81 | FUCA1 (0.55) | S1PR5S1PR1FUCA1TSHRALDH1A1 | |
| SCHEMBL19518531 | 0.81 | FUCA1 (0.55) | S1PR5S1PR1FUCA1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1047695-B1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1192154-B1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| US-6492382-B1 | Dried or frozen pharmaceutical preparation containing a class III antiarrhythmic compound | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| US-6291475-B1 | 3,7-DIAZABICYCLO(3.3.1)NONANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | S1PR5 1338/4885S1PR1 904/4885FUCA1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.